Lansdowne Partners Limited Partnership’s Bristol-Myers Squibb BMY Stock Holding History

Lansdowne Partners Limited Partnership’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	$83.4M	Buy	+1,604,698	New	+$85.4M	0.7%	20

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lansdowne Partners Limited Partnership's BMY Position: Q1 2014 in Review

Lansdowne Partners Limited Partnership opened a new position in Bristol-Myers Squibb (BMY) in Q1 2014: 1,604,698 shares worth $83.4M. The stake represents 0.7% of the portfolio and ranks #20 among its holdings.

1,327 funds tracked by Wall St. Rank hold BMY as of Q1 2014.

Lansdowne Partners Limited Partnership held 1,604,698 shares of Bristol-Myers Squibb worth $83.4M as of Q1 2014.
Bristol-Myers Squibb was a new Lansdowne Partners Limited Partnership position in Q1 2014.
Bristol-Myers Squibb made up 0.7% of Lansdowne Partners Limited Partnership's portfolio in Q1 2014, its #20 holding.
1,327 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2014.

Based on Lansdowne Partners Limited Partnership's 13F filing for Q1 2014, filed 14 May 2014.